Cell Rep March 2022 PMID 35294890

A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors.

Isabel Fernández-Pisonero, Laura Clavaín, Javier Robles-Valero, L Francisco Lorenzo-Martín, Rubén Caloto, Blanca Nieto, Carmen García-Macías, Clara L Oeste, Manuel Sánchez-Martín, Antonio Abad, Alejandro Hortal, Dolores Caballero, Marcos González, Mercedes Dosil, Balbino Alarcón

Full text PDF Download social card

Mentions

Peak: 19 in May 2022

across 3 sources since Mar 2022

Extended reach

239,652

potential audience

Total likes

Video views

3,306

Mentions per month

Mar 2022 – Jul 2022

Where it's discussed

X / Twitter25 posts
YouTube4 videos
News4 articles

AI synopsis

What people are saying

The discussions strongly support the publication’s findings, with posts describing the RRAS2 mutation as a 'potent oncogenic driver' and discussing its implications for therapy, indicating high agreement and perceived impact. The tone is enthusiastic, with words like 'advance' and 'potent,' and examples include mentions of how this discovery opens new treatment avenues, reflecting deep engagement and recognition of the research's significance.

AgreementStrong agreement

Most discussions express strong approval, highlighting the significance of the findings and their potential impact on cancer research.

InterestHigh interest

Posts show high curiosity and enthusiasm, often referencing exciting breakthroughs and advances in understanding tumor drivers.

EngagementModerate engagement

Many comments reference detailed aspects such as the mutation’s role and therapeutic potential, indicating active and thoughtful engagement.

ImpactHigh impact

The discussions consistently emphasize the importance of the research, suggesting it could influence future cancer therapies and understanding of oncogenic processes.

Abstract in brief

A mutation in the RRAS2 gene, similar to known cancer-driving mutations in RAS proteins, acts as a strong oncogenic driver across various tumor types, but its specific role in tumor development in living organisms was previously unclear.
Using a mouse model with an inducible RRAS2 mutation, researchers found that RRAS2 causes rapid tumor formation, which differs from tumors caused by classical RAS genes, and these tumors can be grouped based on their response to treatments.
The study reveals that tumors driven by RRAS2 rely heavily on the mTORC1 pathway for growth, making it a promising target for therapy, especially since these tumors are independent of other common signaling pathways like PI3K, MEK, and Ral.]

Read the full abstract

All mentions

New Oncogenic Gene RRAS2 and Its Therapeutic Vulnerabilities

This video summarizes a scientific article published by Xos Bustelo's team in Cell Reports, March 2022, identifying the RRAS2 gene mutation that promotes various cancers and exploring its mechanisms and potential…

Centro de Investigación del Cáncer_ USAL-CSIC · May 27, 2022 2,523 views

RRAS2 Mutation as a Potent Oncogenic Driver in Various Tumors

A mutation in the RRAS2 gene acts as a strong oncogenic driver across multiple tumor types. Recent research using a mouse model shows RRAS2 causes rapid tumor formation, primarily relying on the mTORC1 pathway for…

Pix Videos Production Company · Jun 3, 2022 509 views

RRAS2 Mutation as a Broad-Oncogenic Driver in Tumors

A mutation in the RRAS2 gene acts as a potent oncogenic driver across various tumor types by promoting rapid tumor formation, primarily through the mTORC1 pathway. These tumors show unique responses to targeted…

Xosé Bustelo · May 26, 2022 147 views

RRAS2 Mutation as a Potent Oncogenic Driver in Tumors

This video summarizes a study published in Cell Reports revealing how mutations in the RRAS2 gene promote various cancers. Using a mouse model, the research shows RRAS2-driven tumors rely on the mTORC1 pathway…

Xosé Bustelo · May 26, 2022 128 views

Biosíntesis podcast

@bio_sintesis · X

RT @XRBustelo:

Jul 17, 2022 · 7 shares · 1,256 followers View post →

Xose R Bustelo

@XRBustelo · X

RT @XRBustelo:

Jul 15, 2022 · 7 shares · 8,548 followers View post →

Xose R Bustelo

@XRBustelo · X

RT @XRBustelo:

Jul 15, 2022 · 8 shares · 8,542 followers View post →

Revista SEBBM

@SEBBM_Revista · X

En @SEBBM_Revista n°212 -junio | Una mutación de RRAS2 actúa como potente inductor oncogénico | Fernández-Pisonero et al. @usal https://t.co/ApSRW6MxL3

Jul 7, 2022 · 542 followers View post →

Pablo Hortal

@PixVideos_ · X

Identification of R-RAS2 as a new oncogenic driver https://t.co/4JjnogNvfV

Jun 4, 2022 · 8 followers View post →

Xose R Bustelo

@XRBustelo · X

RT @XRBustelo:

May 28, 2022 · 7 shares · 8,548 followers View post →

Xose R Bustelo

@XRBustelo · X

RT @XRBustelo:

May 28, 2022 · 8 shares · 8,542 followers View post →

Xose R Bustelo

@XRBustelo · X

RT @CICancer_com: Compartimos el vídeo que explica el avance del laboratorio de @XRBustelo que difundimos en https://t.co/T9iqZozLRd que es…

May 27, 2022 · 1 share · 8,548 followers View post →

Centro de Investigación del Cáncer/CSIC-USAL-FICUS

@ciccancer · X

Compartimos el vídeo que explica el avance del laboratorio de @XRBustelo que difundimos en https://t.co/T9iqZozLRd que está disponible en nuestro canal de YouTube https://t.co/ZqtLfH3Odr

May 27, 2022 · 1 like · 1 share · 4,616 followers View post →

BruzosAliciaL, Dr. (she/her)

@BruzosAliciaL · X

RT @XRBustelo:

May 27, 2022 · 7 shares · 834 followers View post →

Toni Celia-Terrassa

@TCeliaTerrassa · X

RT @XRBustelo:

May 26, 2022 · 7 shares · 1,574 followers View post →

Laura Quevedo

@lauriquepa · X

RT @XRBustelo:

May 26, 2022 · 8 shares · 183 followers View post →

Juan Rodriguez Vita

@J_RodriguezVita · X

RT @XRBustelo:

May 26, 2022 · 8 shares · 2,448 followers View post →

Luis Paz-Ares

@LuisPaz_Ares · X

RT @XRBustelo:

May 26, 2022 · 8 shares · 3,069 followers View post →

Marisol Soengas

@msmelanoma · X

RT @XRBustelo:

May 26, 2022 · 7 shares · 7,974 followers View post →

Grupo R Comunicación

@GrupoRComunica · X

RT @XRBustelo:

May 26, 2022 · 8 shares · 179 followers View post →

RamonReyes

@RamonReyesCC · X

RT @XRBustelo:

May 26, 2022 · 7 shares · 1,270 followers View post →

Javier Robles

@JaviRoblesV · X

RT @XRBustelo:

May 26, 2022 · 8 shares · 289 followers View post →

Conexión Cáncer CSIC

@CancerCSIC · X

RT @XRBustelo:

May 26, 2022 · 8 shares · 991 followers View post →

Xose R Bustelo

@XRBustelo · X

May 26, 2022 · 17 likes · 7 shares · 8,548 followers View post →

Xose R Bustelo

@XRBustelo · X

May 26, 2022 · 36 likes · 8 shares · 8,542 followers View post →

QiDa

@fast04050146 · X

RT @CellReports: A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors https://t.co…

Mar 17, 2022 · 2 shares · 66 followers View post →

Victoria Hendry

@HendryVictoria · X

RT @CellReports: A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors https://t.co…

Mar 17, 2022 · 2 shares · 1,319 followers View post →

Cell Reports

@CellReports · X

A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors https://t.co/DGGCSBaj6r

Mar 17, 2022 · 7 likes · 2 shares · 141,090 followers View post →

Xose R Bustelo

@XRBustelo · X

❓Do you want to see the actual data ? If so, use this link

Mar 16, 2022 · 4 likes · 8,549 followers View post →

A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

New Oncogenic Gene RRAS2 and Its Therapeutic Vulnerabilities

RRAS2 Mutation as a Potent Oncogenic Driver in Various Tumors

RRAS2 Mutation as a Broad-Oncogenic Driver in Tumors

RRAS2 Mutation as a Potent Oncogenic Driver in Tumors